Last $10.12 USD
Change Today +0.16 / 1.61%
Volume 397.6K
INO On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Snapshot

Open
$10.00
Previous Close
$9.96
Day High
$10.17
Day Low
$9.90
52 Week High
02/24/14 - $15.80
52 Week Low
07/15/13 - $4.52
Market Cap
608.8M
Average Volume 10 Days
1.8M
EPS TTM
$-1.40
Shares Outstanding
60.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INOVIO PHARMACEUTICALS INC (INO)

inovio pharmaceuticals inc (INO) Related Bloomberg News

View More Bloomberg News

inovio pharmaceuticals inc (INO) Related Businessweek News

No Related Businessweek News Found

inovio pharmaceuticals inc (INO) Details

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.

71 Employees
Last Reported Date: 03/17/14
Founded in 1979

inovio pharmaceuticals inc (INO) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $852.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.0K
Chief Operating Officer
Total Annual Compensation: $409.8K
Chief Medical Officer
Total Annual Compensation: $414.3K
Compensation as of Fiscal Year 2013.

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals, Inc.(AMEX:INO) added to Russell 2000 Index

Inovio Pharmaceuticals, Inc. will be added to the Russell 2000 Index.

Inovio Pharmaceuticals, Inc.(AMEX:INO) added to Russell 3000 Index

Inovio Pharmaceuticals, Inc. will be added to the Russell 3000 Index.

Inovio Pharmaceuticals Initiates Cervical Cancer Clinical Trial

Inovio Pharmaceuticals, Inc. announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer). This open-label study, called HPV-004, will evaluate INO-3112 in 20 female subjects with inoperable invasive cervical cancer. Subjects will receive four treatments of INO-3112 every four weeks after completion of a standard chemoradiation regimen. Each INO-3112 treatment will be a combination of 6 mg of VGX-3100 and 1 mg of DNA-based IL-12 delivered together intramuscularly with the CELLECTRA(R) delivery system. In a phase I trial of VGX-3100, Inovio demonstrated that this HPV immunotherapy produced high levels of durable T cell immune responses, notably CD8+ T cells, in 78% of all patients. These CD8+ T cells showed the functional ability to kill target cells displaying the antigens E6 and E7. In preclinical animal models, this DNA-based immunotherapy demonstrated 100% protection against HPV E6 and E7-expressing tumors and prevented or delayed the growth of such tumors. The proprietary IL-12 immune activator, called INO-9012, was previously shown to enhance antigen-specific CD4+ and CD8+ T cell immune responses to Inovio's PENNVAX(R) HIV DNA vaccine in a clinical trial. Inclusion of this DNA-based immune activator in INO-3112 is intended to further strengthen the generation of HPV-specific CD8+ T cells to treat HPV-caused cancer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $10.12 USD +0.16

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $1.54 USD +0.02
Peregrine Pharmaceuticals Inc $1.77 USD +0.06
Progenics Pharmaceuticals Inc $4.24 USD -0.02
Vical Inc $1.17 USD 0.00
ZIOPHARM Oncology Inc $3.59 USD +0.22
View Industry Companies
 

Industry Analysis

INO

Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.8x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit www.inovio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.